Edit Business Wire
05 Nov 2013
DUBLIN--(BUSINESS WIRE)--Research and Markets (http.//www.researchandmarkets.com/research/dzsgv6/lu_ae58054) has announced the addition of the "Lu AE58054 (Alzheimer's Disease) - Forecast and Market Analysis to 2022" report to their offering ... Lu AE58054 is a selective serotonin 5-HT6 receptor antagonist under development by H ... - Make more informed business decisions from insightful and in-depth analysis of Lu AE58054 performance ....(size: 3.9Kb)
Edit Seattle Post
25 Oct 2013
Reportbuyer.com just published a new market research report. PharmaPoint. Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 24, 2013. PharmaPoint. Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022. Summary. GlobalData has released its new Country report, “PharmaPoint ... Scope ... 7.10.8 Lu AE58054 107 ... Table 32.Product Profile - Lu AE58054 108. Table 33.Lu AE58054 SWOT Analysis, 2013 110 ... Tel....(size: 8.6Kb)
Edit San Francisco Chronicle
25 Oct 2013
Reportbuyer.com just published a new market research report. PharmaPoint. Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022. London (PRWEB) October 24, 2013. PharmaPoint. Alzheimer’s Disease - UK Drug Forecast and Market Analysis to 2022. Summary. GlobalData has released its new Country report, “PharmaPoint ... Scope ... 7.10.8 Lu AE58054 107 ... Table 32.Product Profile - Lu AE58054 108. Table 33.Lu AE58054 SWOT Analysis, 2013 110 ... Tel....(size: 8.6Kb)
Edit Seattle Post
21 Oct 2013
Reportbuyer.com just published a new market research report. PharmaPoint. Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022. London (PRWEB) October 21, 2013. PharmaPoint. Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022. Summary. GlobalData has released its new Country report, “PharmaPoint ... Scope ... 7.10.10 Lu AE58054 113 ... Table 35.Product Profile - Lu AE58054 114. Table 36.Lu AE58054 SWOT Analysis, 2013 116....(size: 9.0Kb)
Edit Houston Chronicle
21 Oct 2013
Reportbuyer.com just published a new market research report. PharmaPoint. Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022. London (PRWEB) October 21, 2013. PharmaPoint. Alzheimer’s Disease - US Drug Forecast and Market Analysis to 2022. Summary. GlobalData has released its new Country report, “PharmaPoint ... Scope ... 7.10.10 Lu AE58054 113 ... Table 35.Product Profile - Lu AE58054 114. Table 36.Lu AE58054 SWOT Analysis, 2013 116....(size: 9.0Kb)
Edit Business Wire
10 Oct 2013
Lu AE58054 is a selective 5-HT6 receptor antagonist.5 In pre-clinical models, Lu AE58054 was shown to improve cognition1 and enhance the effects of the acetylcholinesterase inhibitor donepezil on hippocampal function.7 A number of early trials have demonstrated that a 5-HT6 receptor antagonist could offer potential benefits in the treatment of ......(size: 16.2Kb)
Edit noodls
10 Oct 2013
The cost to society has been reported as USD ~600 billion per year Lu AE58054 is the third project the two companies are developing together globally, following Abilify Maintena™ and brexpiprazole ... The investigational compound, Lu AE58054 is a selective 5HT6 receptor antagonist with a different proposed mechanism of action than currently available Alzheimer's medications ... About Lu AE58054....(size: 15.3Kb)
Edit StreetInsider
10 Oct 2013
Tweet Send to a Friend. Get Alerts VOLVA Hot Sheet. Price. $0.00 --0%. Trade VOLVA Now!. Join SI PremiumFREE. STOCKHOLM--(BUSINESS WIRE)-- Volvo Trucks (STO ... Source ... Local Businesses Collect Shoes for Soles4Souls Shop Local for a Cause Event Lundbeck and Otsuka Initiate Phase III Clinical Trials on Lu AE58054 as a New Add-on Treatment for Alzheimer's Disease Island Trader Vacations Reviews The 10 Hottest Destination Wedding Spots. ....(size: 4.0Kb)
Edit noodls
16 Jul 2013
Valby, Copenhagen, 2013-07-16 20.28 CEST (GLOBE NEWSWIRE) -- Phase II clinical data show statistically significant improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer's diseasei Lundbeck and Otsuka present data at Alzheimer's Association International Conference 2013 Lu AE58054 is a ......(size: 2.6Kb)
Edit StreetInsider
16 Jul 2013
The 5-HT6-receptor is expressed in brain regions involved in cognition, such as the cortex and the hippocampus, and modulates activity of multiple neurotransmitter systems.viii Lu AE58054 is a selective 5-HT6-receptor antagonist.i In pre-clinical models, Lu AE58054 was shown to improve cognitionii and enhance the effects of the acetylcholinesterase ......(size: 13.9Kb)
Edit Baltimore Sun
16 Jul 2013
The drug, Lu AE58054, showed statistically significant cognitive improvement in a Phase II clinical trial of patients suffering from moderate Alzheimer's, when used as an add-on to the drug donepezil for six months ... "Lu AE58054 potentially represents a new approach to Alzheimer's disease ......(size: 1.5Kb)
Edit Business Wire
26 Mar 2013
(Otsuka) today announced a license and development agreement for Lu AE58054, a selective 5HT6 receptor antagonist currently in development for the treatment of Alzheimer's disease ... Taro Iwamoto, President and Representative Director of Otsuka Pharmaceutical Co., Ltd., noted with respect to Lu AE58054 "The global collaboration between Otsuka and Lundbeck continues to grow stronger with the addition of Lu AE58054....(size: 14.7Kb)
Edit Reuters
26 Mar 2013
* Lundbeck extends alliance with Japan's Otsuka ... Lundbeck shares jumped nearly 12 percent on Tuesday after the company announced the deal for the drug, known as Lu AE58054, and slightly raised its 2013 outlook ... "Lu AE58054 is the first one that we do, but potentially there can be two more," Wiinberg said ... They plan to begin a clinical programme for Lu AE58054 later in 2013 and subsequent studies are expected towards the end of the year....(size: 2.9Kb)